Pantoprazole in the management of dyspepsia in diabetic gastroparesis: evaluating efficacy and safety
DOI:
https://doi.org/10.18203/2349-3933.ijam20253349Keywords:
Proton-pump, Satiety, Glycemic control, Prokinetic, Abdominal discomfortAbstract
Background: Pantoprazole is used in treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD). This questionnaire-based study aims to provide insights into pantoprazole’s real-world effectiveness and safety in managing dyspepsia due to diabetic gastroparesis (DGP).
Methods: This questionnaire-based study was conducted among Indian healthcare professionals (HCP) from September 2024 to March 2025. A questionnaire comprising 13 questions explored preferences of HCPs for use of pantoprazole in last 10 patients with dyspepsia due to diabetic gastroparesis.
Results: A total of 86 HCP were included in this study. The highest percentage of HCPs (30.23%) reported duration of diabetes in patients greater than 10 years with age group of patients 40-60 years. A majority of 89.53% HCPs reported GERD, with abdominal discomfort reported by 38.37% of HCPs. Symptoms like post-prandial fullness and early satiety was observed at frequency of 6/10 patients by 38.37% HCPs, while poor glycemic control at a frequency of 5/10 patients by 38.37% of HCPs. Majority of 59.30% HCPs prescribed pantoprazole treatment for 4 weeks and 95.35% of HCPs added a prokinetic to pantoprazole. The largest proportion of HCPs (43.02%) reported symptom relief in 8/10 patients with 48.84% of HCPs observed glycemic control improvement in <8 patients. Loose stools were the most commonly reported adverse effect by 70.93% of HCPs. Approximately 90% of HCPs rated pantoprazole's efficacy, safety and adherence to treatment as excellent and good.
Conclusion: This study revealed strong clinical, therapeutic, and patient-centric outcomes across India for use of pantoprazole in patients with dyspepsia due to DGP.
Metrics
References
Sato H, Grover M. Gastroparesis and functional dyspepsia: spectrum of gastroduodenal neuromuscular disorders or unique entities? Gastro Hep Advances. 2023;2(3):438-48. DOI: https://doi.org/10.1016/j.gastha.2022.10.005
Francis P, Zavala SR. Functional Dyspepsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
Kim BJ, Kuo B. Gastroparesis and functional dyspepsia: a blurring distinction of pathophysiology and treatment. J Neurogastroenterol Motility. 2019;25(1):27-35. DOI: https://doi.org/10.5056/jnm18162
Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pellicano R. Management of dyspepsia and gastroparesis in patients with diabetes. A clinical point of view in the year 2021. J Clin Med. 2021;10(6):1313. DOI: https://doi.org/10.3390/jcm10061313
Uppaluri S, Jain MA, Ali H, Shingala J, Amin D, Ajwani T, et al. Pathogenesis and management of diabetic gastroparesis: An updated clinically oriented review. Diabetes & Metabolic Syndrome: Clin Res Rev. 2024:102994. DOI: https://doi.org/10.1016/j.dsx.2024.102994
Alam U, Asghar O, Malik RA. Diabetic gastroparesis: Therapeutic options. Diabetes Therapy. 2010;1:32-43. DOI: https://doi.org/10.1007/s13300-010-0010-8
Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. DOI: https://doi.org/10.1002/14651858.CD011194.pub2
Mönnikes H, Schwan T, Van Rensburg C, Straszak A, Theek C, Sander P, et al. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro‐oesophageal reflux disease. Alimentary Pharmacol Therapeutics. 2012;35(11):1279-89. DOI: https://doi.org/10.1111/j.1365-2036.2012.05085.x
Bernshteyn MA, Masood U. Pantoprazole. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
Caturano A, Cavallo M, Nilo D, Vaudo G, Russo V, Galiero R, et al. Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions. Gastroint Dis. 2024;6(1):214-29. DOI: https://doi.org/10.3390/gidisord6010016
Fass R, McCallum RW, Parkman HP. Treatment challenges in the management of gastroparesis-related GERD. Gastroenterol Hepatol. 2009;5:4.
Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clinical Gastroenterol Hepatol. 2010;8(8):676-81. DOI: https://doi.org/10.1016/j.cgh.2010.04.027
Parkman HP, Hallinan EK, Hasler WL, Farrugia G, Koch KL, Nguyen L, et al. Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motility. 2017;29(4):e12981. DOI: https://doi.org/10.1111/nmo.12981
Homko C, Siraj ES, Parkman HP. The impact of gastroparesis on diabetes control: Patient perceptions. J Diabetes Complications. 2016;30(5):826-9. DOI: https://doi.org/10.1016/j.jdiacomp.2016.03.025
Lakhtakia S, Singh AP, Singla N, Memon SF, Reddy DN. Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open‐label, single‐arm pilot study. JGH Open. 2024;8(2):e12988. DOI: https://doi.org/10.1002/jgh3.12988
González-Ortiz M, Martínez-Abundis E, Mercado-Sesma AR, Álvarez-Carrillo R. Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;108(1):e11-3. DOI: https://doi.org/10.1016/j.diabres.2015.01.039
Downloads
Published
How to Cite
Issue
Section
